No Data
Solasia Pharma KK: Notice regarding revisions to full-year earnings forecasts and the status of derivation of Dalbias China rights
The Tokyo Stock Exchange Growth Index fell sharply, remaining in the negative territory throughout the day.
Tokyo Stock Exchange Growth Market Index 816.20 -10.08 / Volume 10.1616 million shares / Trading value 108.8 billion yen. Tokyo Stock Exchange Growth Market 250 Index 638.08 -8.67 / Volume 10.14 million shares / Trading value 84.5 billion yen. Today's growth market saw significant declines in the Tokyo Stock Exchange Growth Market Index and the Tokyo Stock Exchange Growth Market 250 Index, with 157 gaining stocks, 391 declining stocks, and 44 unchanged. Today's growth market had a weak performance. The US market on the previous three days
The Tokyo Stock Exchange Gross Index is slightly down, with dull price movements due to selling and buying crossing each other.
Tokyo Stock Exchange Growth Market Index 814.57 -0.22 / Volume 0.2 billion 71.4 million shares / Trading value 129.1 billion yen Tokyo Stock Exchange Growth Market 250 Index 634.81 -0.83 / Volume 0.1 billion 15.25 million shares / Trading value 89.1 billion yen Today's growth market, Tokyo Stock Exchange Growth Market Index and Tokyo Stock Exchange Growth Market 250 Index are slightly lower, with 272 gainers, 269 decliners, and 49 unchanged. Today's growth market saw a conflicting trend of selling and buying. The 21st of the previous day.
Ranking of volume change rate (10 am slot) - Data SEC, JGB double, etc. are ranked.
In the volume change rate ranking, by comparing the average volume over the last five days with the volume on the distribution day, one can understand the trends in stock selection and the interests of market participants. ■ Top Volume Change Rates [As of November 22, 10:32] (Comparison of the average volume over the last five days) Stock Code Stock Name Volume 5-Day Average Volume Volume Change Rate Stock Price Change Rate <2251> JGB Double 3381101432.177388.78%0.0002%<9161>
Solasia Pharma KK: Business Status of Product Development Products, etc. (3rd quarter of the fiscal year ending 2024/12)
Solasia Pharma KK: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/12 [IFRS] (consolidated)
No Data